Annabel Samimy
Stock Analyst at Stifel
(3.50)
# 893
Out of 5,038 analysts
49
Total ratings
45.65%
Success rate
34.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $60 → $80 | $73.32 | +9.11% | 2 | Sep 24, 2025 | |
| GPCR Structure Therapeutics | Initiates: Buy | $50 | $26.66 | +87.55% | 1 | Jan 8, 2025 | |
| ALT Altimmune | Initiates: Buy | $18 | $3.90 | +361.54% | 1 | Jan 8, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 → $17 | $5.35 | +217.76% | 4 | Nov 22, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $40 | $14.78 | +170.64% | 1 | Oct 8, 2024 | |
| KMDA Kamada | Initiates: Buy | $18 | $6.80 | +164.71% | 1 | Jul 3, 2024 | |
| PHAT Phathom Pharmaceuticals | Initiates: Buy | $24 | $13.46 | +78.31% | 1 | May 3, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $40 | $12.19 | +228.14% | 2 | Apr 12, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $80 | $31.42 | +154.61% | 6 | Mar 15, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $225 → $230 | $138.52 | +66.04% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $25 | $6.82 | +266.57% | 1 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $21.20 | +65.09% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $65 | $28.14 | +130.99% | 3 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $700 → $275 | $11.18 | +2,359.75% | 4 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $42.04 | +7.04% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $120 | $3.77 | +3,083.02% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $2.42 | +893.79% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $1.22 | +61,375.41% | 3 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $24 | $50.67 | -52.63% | 7 | Apr 16, 2020 |
Palvella Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $60 → $80
Current: $73.32
Upside: +9.11%
Structure Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $50
Current: $26.66
Upside: +87.55%
Altimmune
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $3.90
Upside: +361.54%
Inventiva
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $5.35
Upside: +217.76%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $40
Current: $14.78
Upside: +170.64%
Kamada
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $6.80
Upside: +164.71%
Phathom Pharmaceuticals
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $13.46
Upside: +78.31%
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $12.19
Upside: +228.14%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $31.42
Upside: +154.61%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $138.52
Upside: +66.04%
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $6.82
Upside: +266.57%
Oct 5, 2023
Initiates: Buy
Price Target: $35
Current: $21.20
Upside: +65.09%
Aug 29, 2023
Maintains: Buy
Price Target: $60 → $65
Current: $28.14
Upside: +130.99%
Jun 26, 2023
Downgrades: Hold
Price Target: $700 → $275
Current: $11.18
Upside: +2,359.75%
Mar 7, 2023
Initiates: Buy
Price Target: $45
Current: $42.04
Upside: +7.04%
Nov 10, 2022
Upgrades: Buy
Price Target: $120
Current: $3.77
Upside: +3,083.02%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $2.42
Upside: +893.79%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $1.22
Upside: +61,375.41%
Apr 16, 2020
Maintains: Hold
Price Target: $25 → $24
Current: $50.67
Upside: -52.63%